PURPOSE: Cancer cachexia is a common problem among advanced cancer patients. A mixture of beta-hydroxyl beta-methyl butyrate, glutamine, and arginine (HMB/Arg/Gln) previously showed activity for increasing lean body mass (LBM) among patients with cancer cachexia. Therefore a phase III trial was implemented to confirm this activity. MATERIALS AND METHODS: Four hundred seventy-two advanced cancer patients with between 2% and 10% weight loss were randomized to a mixture of beta-hydroxyl beta-methyl butyrate, glutamine, and arginine or an isonitrogenous, isocaloric control mixture taken twice a day for 8 weeks. Lean body mass was estimated by bioimpedance and skin-fold measurements. Body plethysmography was used when available. Weight, the Schwartz Fatigue Scale, and the Spitzer Quality of Life Scale were also measured. RESULTS: Only 37% of the patients completed protocol treatment. The majority of the patient loss was because of patient preference (45% of enrolled patients). However, loss of power was not an issue because of the planned large target sample size. Based on an intention to treat analysis, there was no statistically significant difference in the 8-week lean body mass between the two arms. The secondary endpoints were also not significantly different between the arms. Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08). Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints. The secondary endpoints were also not significantly different between the arms. CONCLUSION: This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients. Possible contributing factors beyond the efficacy of the intervention were the inability of patients to complete an 8-week course of treatment and return in a timely fashion for follow-up assessment, and because the patients may have only had weight loss possible not related to cachexia, but other causes of weight loss, such as decreased appetite. However, there was a strong trend towards an increased body mass among patients taking the Juven compound using the secondary endpoint of AUC.
RCT Entities:
PURPOSE:Cancer cachexia is a common problem among advanced cancerpatients. A mixture of beta-hydroxyl beta-methyl butyrate, glutamine, and arginine (HMB/Arg/Gln) previously showed activity for increasing lean body mass (LBM) among patients with cancer cachexia. Therefore a phase III trial was implemented to confirm this activity. MATERIALS AND METHODS: Four hundred seventy-two advanced cancerpatients with between 2% and 10% weight loss were randomized to a mixture of beta-hydroxyl beta-methyl butyrate, glutamine, and arginine or an isonitrogenous, isocaloric control mixture taken twice a day for 8 weeks. Lean body mass was estimated by bioimpedance and skin-fold measurements. Body plethysmography was used when available. Weight, the Schwartz Fatigue Scale, and the Spitzer Quality of Life Scale were also measured. RESULTS: Only 37% of the patients completed protocol treatment. The majority of the patient loss was because of patient preference (45% of enrolled patients). However, loss of power was not an issue because of the planned large target sample size. Based on an intention to treat analysis, there was no statistically significant difference in the 8-week lean body mass between the two arms. The secondary endpoints were also not significantly different between the arms. Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08). Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints. The secondary endpoints were also not significantly different between the arms. CONCLUSION: This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancerpatients. Possible contributing factors beyond the efficacy of the intervention were the inability of patients to complete an 8-week course of treatment and return in a timely fashion for follow-up assessment, and because the patients may have only had weight loss possible not related to cachexia, but other causes of weight loss, such as decreased appetite. However, there was a strong trend towards an increased body mass among patients taking the Juven compound using the secondary endpoint of AUC.
Authors: Don E Smith; Jeff Hudson; Allison Martin; Judith Freund; Matthew R Griffiths; Sue Kalnins; Matthew Law; Andrew Carr; David A Cooper Journal: HIV Clin Trials Date: 2003 Jan-Feb
Authors: Kent Lundholm; Ulla Körner; Lena Gunnebo; Petra Sixt-Ammilon; Marita Fouladiun; Peter Daneryd; Ingvar Bosaeus Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Cagdas Yavas; Guler Yavas; Hilal Acar; Hatice Toy; Deniz Yuce; Serap Akyurek; Ozlem Ata Journal: Support Care Cancer Date: 2012-09-21 Impact factor: 3.603
Authors: Sally Wheelwright; Anne-Sophie Darlington; Jane B Hopkinson; Deborah Fitzsimmons; Alice White; Colin D Johnson Journal: Support Care Cancer Date: 2013-06-25 Impact factor: 3.603
Authors: D Tomlinson; P D Robinson; S Oberoi; D Cataudella; N Culos-Reed; H Davis; N Duong; F Gibson; M Götte; P Hinds; S L Nijhof; P van der Torre; S Cabral; L L Dupuis; L Sung Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677